东阿阿胶(000423) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥437,737,253.85, a decrease of 66.11% compared to ¥1,291,783,493.19 in the same period last year[3] - The net profit attributable to shareholders was -¥83,867,522.88, representing a decline of 121.33% from ¥393,179,922.82 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥93,809,543.32, down 125.48% from ¥368,111,454.11 in the previous year[3] - The net profit for Q1 2020 was a loss of CNY 91,252,572.15, compared to a profit of CNY 471,179,577.73 in the same period last year[31] - The total comprehensive income for the first quarter was -84,197,169.43 CNY, compared to 374,012,876.56 CNY in the same period last year[32] - The net profit for the first quarter of 2020 was -84,197,169.43 CNY, a significant decrease from 389,948,990.41 CNY in the same period last year[32] Cash Flow - The net cash flow from operating activities improved to ¥216,072,249.65, a 134.15% increase from -¥632,632,219.50 in the same period last year[3] - The net cash flow from operating activities was 216,072,249.65 CNY, a significant improvement compared to -632,632,219.50 CNY in the previous period[36] - The total cash outflow from operating activities was 670,117,035.68 CNY, compared to 1,581,636,533.53 CNY in the previous period[36] - The cash inflow from investment activities was significantly lower than the previous period, which was 2,057,884,767.36 CNY[36] - The net cash flow from financing activities was -128,885,377.90 CNY, compared to -6,301,908.09 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period amounted to 1,955,914,760.92 CNY, up from 1,926,052,316.22 CNY in the previous period[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,096,986,612.25, a decrease of 4.78% from ¥11,653,674,527.93 at the end of the previous year[3] - The total current assets decreased to ¥7,640,676,324.78 from ¥8,194,201,087.88, representing a decline of about 6.8%[23] - The total liabilities decreased from ¥1,630,611,386.48 to ¥1,280,704,318.12, reflecting a reduction of about 21.5%[25] - The company's total assets as of March 31, 2020, were CNY 11,258,615,858.37, a decrease from CNY 11,491,856,219.50 at the end of 2019[29] - The total liabilities as of March 31, 2020, were CNY 1,428,624,286.65, slightly down from CNY 1,443,237,236.23 at the end of 2019[29] Shareholder Information - The top two shareholders, China Resources Dong'e Ejiao Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd., held 23.14% and 8.86% of the shares, respectively[7] - The total number of ordinary shareholders at the end of the reporting period was 92,890[6] - The total equity attributable to shareholders of the parent company was CNY 9,829,991,571.72, a decrease from CNY 10,048,618,983.27 at the end of 2019[29] Operating Costs and Expenses - Operating costs decreased by 31.90% to RMB 290.53 million from RMB 426.59 million in the previous period, reflecting lower sales[12] - The company reported a 62.68% reduction in taxes payable, amounting to RMB 18.63 million compared to RMB 49.92 million in the previous period[12] - The company’s financial expenses increased significantly by 209.66%, resulting in a loss of RMB 5.37 million due to reduced interest income and exchange rate declines[12] - The company’s investment income dropped by 75.50% to RMB 508,277.77 from RMB 2.07 million in the previous period, primarily due to decreased returns from financial products[12] - The company's operating expenses, including sales and management costs, saw significant reductions due to the pandemic, with sales expenses down by 52.19%[12] Other Financial Metrics - The basic earnings per share were -¥0.1291, down 121.47% from ¥0.6012 in the same period last year[3] - The weighted average return on equity was -0.79%, a decline of 4.21% from 3.42% year-on-year[3] - Research and development expenses were 35,605,925.73 CNY, a decrease of 43.3% from 62,758,422.27 CNY in the prior year[33] - The gross profit margin decreased, with cost of goods sold at 126,575,604.74 CNY compared to 299,282,085.53 CNY in the previous year[33]